PLDT Inc. Sponsored ADR (PHI)

Cost of Revenue

₱56.92B

TTM · Period ending: · PHP

PHI logo

PHI Cost of Revenue

Latest reported₱56.92B PHP
PHI TTM Cost of Revenue · PHP (₱0.00 → ₱56.92B)
High-resolution chart · PNG

PHI cost of revenue history

Trailing twelve months (TTM) · PHP. Each value covers four complete reported quarters.

PLDT Inc. Sponsored ADR Cost of Revenue — Trailing twelve months (TTM) (PHP)
Period endingCost of Revenue (PHP)
56,924,031,000
55,883,031,000
46,380,031,000
29,452,000,000
29,483,000,000
28,815,000,000
39,427,000,000
61,416,000,000
60,641,000,000
59,738,000,000
47,962,000,000
24,043,000,000
23,520,000,000
22,426,000,000
20,621,000,000
19,867,000,000
18,126,000,000
17,479,000,000
17,039,000,000
16,219,000,000
16,608,000,000
15,531,000,000
14,441,000,000
15,200,000,000
15,321,000,000
17,918,000,000
19,121,000,000
19,097,000,000
20,397,000,000
20,804,000,000
21,758,000,000
22,759,000,000
21,938,000,000
20,868,000,000
20,426,000,000
20,107,000,000
21,139,000,000
24,279,000,000
26,902,000,000
28,966,000,000
29,723,000,000
28,313,000,000
26,931,000,000
25,319,000,000
24,694,000,000
24,194,000,000
24,019,000,000
24,065,000,000
23,724,000,000
23,638,000,000
22,514,000,000
30,417,000,000
26,812,000,000
22,683,000,000
20,303,000,000
31,218,000,000
30,497,000,000
29,799,000,000
28,420,000,000
14,227,000,000
14,222,000,000
14,264,000,000
14,205,000,000
5,122,000,000
5,258,000,000
5,419,000,000
5,431,000,000
5,501,605,100
5,517,169,300
5,528,614,220
5,219,795,060
4,690,388,820
4,489,572,370
4,525,679,310
4,851,349,470
6,052,773,060
6,181,276,560
5,975,699,060
6,004,218,380
5,723,090,180
5,984,613,560
7,787,849,340
8,587,876,260
9,205,831,670
10,502,046,040
10,333,978,810
10,329,053,650
23,577,372,027
21,279,372,085
21,797,256,175
23,373,768,332
18,332,626,825
19,495,496,088
17,948,579,783
16,250,044,267
3,236,682,910
5,030,330,897
6,666,209,814
8,116,107,594
16,539,604,558
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.